

# Leukaemia Section

## Short Communication

### t(6;9)(p22;q34) DEK/NUP214 in Childhood

Henrik Hasle, Julie Damgaard Sandahl

Department of Pediatrics, Aarhus University Hospital, Skejby, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark; hasle@dadlnet.dk, Julie.damgaard@gmail.com

Published in Atlas Database: November 2016

Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/t0609p22q34ChildID1359.html>

Printable original version : <http://documents.irevues.inist.fr/bitstream/handle/2042/68533/11-2016-t0609p22q34ChildID1359.pdf>

DOI: 10.4267/2042/68533

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.

© 2017 *Atlas of Genetics and Cytogenetics in Oncology and Haematology*

#### Abstract

Review on t(6;9)(p22;q34) DEK/NUP214 in Childhood, with data on clinics, and the genes involved.

#### Keywords

DEK; NUP214; Childhood; acute myeloid leukemia; myelodysplastic syndrome

#### Clinics and pathology

##### Disease

Acute myeloid leukemias 1238 (AML) and myelodysplastic syndromes (MDS)

##### Phenotype/cell stem origin

t(6;9)(p22;q34) is a rare subtype of pediatric AML earlier only described in small series and case reports (Gupta, et al 2010, Ishiyama, et al 2012, Slovak, et al 2006). Two large studies both published in 2014 described the clinical, morphologic, and genetic characteristics: the I-BFM-study including 62 children of which 54 was diagnosed as AML and 8 as MDS, and the COG study investigating 48 children all diagnosed as AML (Sandahl, et al 2014, Tarlock, et al 2014). This review is based upon the 110 children from these two series. There are no pediatric studies of stem cell origin. AML in children with t(6;9) is associated with French-American-British (FAB) type M2 (44%) and FAB type M4 (25%) (Sandahl, et al 2014, Tarlock, et al 2014).

##### Epidemiology


The t(6;9)(p22;q34) was first described in a pediatric patient in 1982 (Kaneko, et al 1982). It is rare, found in only about 1% of all pediatric AML (Sandahl, et al 2014, Slovak, et al 2006, Tarlock, et al 2014) and associated with late onset with a median age 11 years and no patients below 2 years of age (Sandahl, et al 2014, Tarlock, et al 2014). There is an equal sex distribution with 53% males.

##### Cytology

Basophilia is common in adults with t(6;9). In the I-BFM study, peripheral blood smears from 11 children and bone marrow smears from 15 children with t(6;9)(p22;q34) were evaluable for central review (Sandahl, et al 2014).

All had mild to moderate bilinear dysplasia. Basophils were present in five patients (33%), four of which had 2% basophils, one patient (6%) had 1% basophils, none had > 2%.

From the remaining 47 AML patients, reports on basophils were available in 16 cases; four patients had 1-2% basophils in BM smears, one had 0.4%, and no basophils were reported in the remaining 11. No Auer rods were seen in this reviewed pediatric series. Pseudo-Pelger cells were found in all reviewed material. Furthermore, almost all had tadpole blasts and many have bilobar blasts, both characteristic of AML-M3. However no patients were classified as FAB M3.



BM biopsies from pediatric t(6;9) AML illustrating morphologic characteristics A Pseudo-Pelger-Huet anomaly tadpole blasts. Illustration from central review by Gitte Kerndrup (2013)

### Treatment

It has been suggested that Hematopoietic stem cell transplantation (HSCT) in first complete remission may improve outcome. In the I-BFM-study, the 5-year event-free survival was improved among patients treated the HSCT in CR1 compared with chemotherapy alone (68% vs. 18%;  $P < 0.01$ ) but it did not effect the OS (68% vs. 54%;  $P = 0.48$ ). In the COG study those who received HSCT in CR1 or CR2 had a survival of 60% vs. 21% in those treated with chemotherapy alone (Tarlock, et al 2014).

### Prognosis

Complete remission rate is significantly lower compared with pediatric AML patients without t(6;9) (Tarlock, et al 2014), but reported CR rates varied between 67 and 93%. (Sandahl, et al 2014, Tarlock, et al 2014) Furthermore, t(6;9) was associated with high risk of relapse 57%-64%, low 5-year EFS of 32% and 5-year OS around 45% (Sandahl, et al 2014, Tarlock, et al 2014). The outcome seems better among pediatric t(6,9) patients compared with adults (Slovak, et al 2006). (Ishiyama, et al 2012, Slovak, et al 2006). Among t(6;9) patients FLT3-ITD had a non-significant negative influence on survival with a 5-year overall survival compared with non-FLT3-ITD (22% versus 62%;  $p = 0.13$ ) in the I-BFM study (Sandahl, et al 2014). The OS in the COG study was

in contrast higher with FLT3-ITD than without (40% vs. 27%;  $p > 0.9$ ) which may be explained by FLT3-ITD being allocated to hematopoietic stem cell transplantation (HSCT) (Sandahl, et al 2014, Tarlock, et al 2014)

## Genetics

The t(6;9) is often associated with FLT3-ITD reported in 42% to 69% (Sandahl, et al 2014, Slovak, et al 2006, Tarlock, et al 2014).

In the I-BFM study, the gene expression profile was analyzed in 297 pediatric AML patients including eight t(6;9) AML cases. The t(6,9) cases had a significant signature with high expression levels of HOXA and the HOXB (HOXB2, (HOXB3, (HOXB4, HOXB5, HOXB6, HOXB8, and HOXB9) genes described previously (Hollink, et al 2011) but also with high expression of HIST2H4A, PRDM2 (RIZ), SESN1, and EYA3 (Sandahl, et al 2014).

## Cytogenetics

### Cytogenetics morphological

The translocation is easily detected by conventional karyotyping, only 4/62 pediatric cases were discovered solely by FISH or PCR (Sandahl, et al 2014).

### Additional anomalies

t(6;9)(p22;q34) often presents as the sole cytogenetic abnormality (81%). (Gupta, et al 2010). Additional abnormalities are described in 12-19%. (Sandahl, et al 2014) Recurrent aberrations in addition to t(6;9) have been described in 19% with loss of chromosome Y in three boys and trisomy 8 and trisomy 13 each present in three cases, either alone or combined (Sandahl, et al 2014).

## Genes involved and proteins

### DEK (DEK proto-oncogene)

#### Location

6p22.3

#### Protein

375 amino-acids; DEK contains acidic domains (Asp/Glu-rich), a SAF/SAP box, a nuclear localisation signal; and other DNA binding domains. Highly conserved nuclear factor; chromatin remodeling protein, essential for heterochromatin integrity; DEK localizes preferentially at sites proximal to the promoters of expressed genes; acts as a repressor of transcription by interfering with histone acetyl-transferases and as an activator of transcription by stimulating the binding of TFAP2A (the activator protein AP2-alpha) to its target DNA sequences; DEK introduces super-coils into circular

DNA (in Oancea et al., 2010). DEK is a regulator of stem and progenitor cells and is upregulated in a number of neoplasms (breast cancer, chronic lymphocytic leukemia, small cell lung carcinoma, Merkel cell carcinoma, melanoma, glioblastoma, retinoblastoma, cervical, and bladder cancers) (review in Riveiro-Falkenbach and Soengas, 2010); CEBPA and DEK coordinately activate myeloid gene expression (Koleva et al., 2012); DEK is an estrogen receptor alpha (ESR1) target gene (Privette Vinnedge et al., 2012). DEK expression modulates ATM and DNA-dependent protein kinase signaling, and contributes to DNA repair (Kavanaugh et al., 2011).

### **NUP214 (nucleoporin 214kDa)**

#### **Location**

9q34.13

#### **Note**

The previous name of NUP214 was CAN.

#### **Protein**

2090 amino acids; contains dimerization domains (2 leucine zippers) and FG repeats; forms homodimers; the C-terminus is essential; the N-terminus is involved in mRNA export (Köser et al., 2005). Nuclear membrane localisation (cytoplasmic face of nucleopore); component of the nuclear pore complex; involved in nucleo-cytoplasmic transport.

## **Result of the chromosomal anomaly**

### **Hybrid gene**

#### **Description**

5' DEK - 3' NUP214 on der(6); head to tail DEK/NUP214 fusion gene (SET/NUP214 exceptional); breakpoint clusters in a single intron of 8 kb (ICB9: 'intron containing breakpoint 9') in NUP214, and in a single intron (of 12 kb) as well (ICB6) in DEK.

#### **Transcript**

5.5 kb RNA; no NUP214-DEK reciprocal transcript on chromosome 9.

#### **Detection**

RNA-PCR.

### **Fusion protein**

#### **Description**

165 kDa; N-term with almost the entire DEK protein fused to the C-terminal two-thirds of the

NUP214 protein.

#### **Expression / Localisation**

Nuclear localisation.

## **References**

Gupta M, Ashok Kumar J, Sitaram U, Neeraj S, Nancy A, Balasubramanian P, Abraham A, Mathews V, Viswabandya A, George B, Chandy M, Srivastava A, Srivastava VM. The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 cases. *Cancer Genet Cytogenet.* 2010 Dec;203(2):297-302

Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, van Galen JF, Beverloo HB, Sonneveld E, Kaspers GJ, Trka J, Baruchel A, Zimmermann M, Creutzig U, Reinhardt D, Pieters R, Valk PJ, Zwaan CM. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. *Blood.* 2011 Sep 29;118(13):3645-56

Ishiyama K, Takami A, Kanda Y, Nakao S, Hidaka M, Maeda T, Naoe T, Taniguchi S, Kawa K, Nagamura T, Tabuchi K, Atsuta Y, Sakamaki H. Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant. *Leukemia.* 2012 Jun;26(6):1416-9

Kaneko Y, Rowley JD, Maurer HS, Variakojis D, Moehr JW. Chromosome pattern in childhood acute nonlymphocytic leukemia (ANLL). *Blood.* 1982 Aug;60(2):389-99

Sandahl JD, Coenen EA, Forestier E, Harbott J, Johansson B, Kerndrup G, Adachi S, Auvrignon A, Beverloo HB, Cayuela JM, Chilton L, Fornerod M, de Haas V, Harrison CJ, Inaba H, Kaspers GJ, Liang DC, Locatelli F, Masetti R, Perot C, Raimondi SC, Reinhardt K, Tomizawa D, von Neuhoff N, Zecca M, Zwaan CM, van den Heuvel-Eibrink MM, Hasle H. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. *Haematologica.* 2014 May;99(5):865-72

Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Bennett JM, Stirewalt DL, Meshinchi S, Willman CL, Ravindranath Y, Alonzo TA, Carroll AJ, Raimondi SC, Heerema NA. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. *Leukemia.* 2006 Jul;20(7):1295-7

Tarlock K, Alonzo TA, Moraleta PP, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS, Meshinchi S. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group. *Br J Haematol.* 2014 Jul;166(2):254-259

---

*This article should be referenced as such:*

Hasle H, Sandahl JD. t(6;9)(p22;q34) DEK/NUP214 in Childhood. *Atlas Genet Cytogenet Oncol Haematol.* 2017; 21(8):303-305.

---